---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-24-004225"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:18:12.980638+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tonix announces $4.4M offering at $0.30 per share; lowers existing warrant exercise prices to $0.33

## Summary
- Gross proceeds of ~$4.4M from sale of 14.7M shares and 14.7M Series E warrants at $0.30 combined price.
- Series E warrants exercisable at $0.33, begin 6 months from issuance, expire in 5.5 years.
- Existing warrants from Aug/Oct/Dec 2023 amended to exercise price $0.33 and extended expiration dates, subject to shareholder approval.
- Proceeds to be used for working capital, general corporate purposes, and to satisfy a portion of debt.
- Closing expected April 1, 2024; A.G.P./Alliance Global Partners acts as placement agent with 7% fee.

## SEC filing metadata
- accession: 0001999371-24-004225
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937124004225/0001999371-24-004225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937124004225/tnxp_8k-032824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-24-004225
- JSON: https://secwatch.observer/filing/0001999371-24-004225.json
- Plain text: https://secwatch.observer/filing/0001999371-24-004225.txt

## Key facts
- Material Agreements
  Tonix Pharmaceuticals Holding Corp. entered into Purchase Agreement with certain institutional investors valued at up to approximately $4.4 million (effective 2024-03-28).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: up to approximately $4.4 million
  - Effective: 2024-03-28
  source text: On March 28, 2024, Tonix Pharmaceuticals Holding Corp. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (collectively, the “Purchasers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1430306/000199937124004225/0001999371-24-004225-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.